# US 2025/0058000 A1 · Treatment of Proliferative Disorders Using Antibodies to PSMA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0058000 A1
- Document ID: US20250058000A1
- Status: Published application
- Kind: A1
- Application number: 18/641,102
- Filed: 2024-04-19
- Published: 2025-02-20
- Earliest claimed: 2007-10-03
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Neil H. Bander
- Web page: https://patentgrep.com/patent/US20250058000A1

## CPC

- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K 51/1072: {the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y10T 436/147777: Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA after first administering a hormonal therapy.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method of treating a prostate cancer in a patient in need thereof comprising administering an antibody or antigen binding fragment thereof that is capable of binding to an extracellular domain of PSMA wherein the antibody or antigen binding fragment is conjugated to Lutetium-177 or other short range isotope wherein a first dose of the antibody or antigen binding fragment thereof is administered to the patient two to four weeks after beginning administration of hormonal therapy to the patient.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antibody or antigen binding fragment thereof is an agent capable of eliciting an antibody-dependent cellular cytotoxic response.

### Claim 17 (depends on 15)

The method of claim 15, further comprising measuring the amount of PSMA on PSMA expressing cells of the patient, and wherein the first dose of the antibody or antigen binding fragment thereof is administered when the amount of PSMA on PSMA expressing cells of the patient has increased by five-fold or more.

### Claim 18 (depends on 15)

The method of claim 15, further comprising measuring the amount of PSMA on PSMA expressing cells of the patient and wherein the first dose of the antibody or antigen binding fragment thereof is administered one to five days after the amount of PSMA on PSMA expressing cells of the patient has increased by five-fold or more.

### Claim 19 (depends on 15)

The method of claim 15, further comprising measuring the amount of PSMA on PSMA expressing cells of the patient and wherein the first dose of the antibody or antigen binding fragment thereof is administered within one day to five days after the amount of PSMA on PSMA expressing cells has increased by nine-fold or more.

### Claim 20 (depends on 15)

The method of claim 15, further comprising monitoring serum testosterone levels in the patient.

### Claim 21 (depends on 15)

The method of claim 15, wherein the prostate cancer is early stage, non-bulky prostate cancer.

### Claim 22 (depends on 15)

The method of claim 15, wherein the first dose of the antibody or antigen binding fragment thereof is administered to the patient two to three weeks after beginning administration of hormonal therapy to the patient or three to four weeks after beginning administration of hormonal therapy to the patient.

### Claim 23 (depends on 15)

The method of claim 15, wherein the first dose of the antibody or antigen binding fragment thereof is administered to the patient two to three weeks after beginning administration of hormonal therapy to the patient.

### Claim 24 (depends on 15)

The method of claim 15, wherein the first dose of the antibody or antigen binding fragment thereof is administered to the patient three to four weeks after beginning administration of hormonal therapy to the patient.

### Claim 25 (depends on 16)

The method of claim 16, further comprising measuring the amount of PSMA on PSMA expressing cells of the patient, and wherein the first dose of the antibody or antigen binding fragment thereof is administered when the amount of PSMA on PSMA expressing cells of the patient has increased by five-fold or more.

### Claim 26 (depends on 25)

The method of claim 25, further comprising measuring the amount of PSMA on PSMA expressing cells of the patient and wherein the first dose of the antibody or antigen binding fragment thereof is administered within one day to five days after the amount of PSMA on PSMA expressing cells has increased by nine-fold or more.

### Claim 27 (depends on 26)

The method of claim 26, further comprising monitoring serum testosterone levels in the patient.

### Claim 28 (depends on 27)

The method of claim 27, wherein the prostate cancer is early stage, non-bulky prostate cancer.
